Purpose Of Review: The molecular imaging field has been very instrumental in identifying the multiple network interactions that compose the human brain. The cerebral glucose metabolism is associated with neural function. 18F-fluoro-deoxyglucose-PET (FDG-PET) studies reflect brain metabolism in a pattern-specific manner. This article reviews FDG-PET studies in Parkinson's disease (PD), atypical parkinsonism (AP), Huntington's disease (HD), and dystonia.
Recent Findings: The metabolic pattern of PD, disease progression, non-motor symptoms such as fatigue, depression, apathy, impulse control disorders, and cognitive impairment, and the risk of progression to dementia have been identified with FDG-PET studies. In prodromal PD, the REM sleep behavior disorder-related covariance pattern has been described. In AP, FDG-PET studies have demonstrated to be superior to D2/D3 SPECT in differentiating PD from AP. The metabolic patterns of HD and dystonia have also been described. FDG-PET studies are an excellent tool to identify patterns of brain metabolism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11910-019-0966-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Meta-analysis of 68Ga-FAPI PET in Assessment of Ovarian Cancer.
Acad Radiol
March 2025
Department of Nuclear Medicine, Beijing Luhe Hospital, Capital Medical University, Xinhua Road 82, Tong Zhou District, 101199 Beijing, China.
Rationale And Objectives: The objective of this research is to carry out a systematic review and meta-analysis to detect the diagnostic efficacy of 68Ga-FAPI Positron Emission Tomography (PET) Computed Tomography/Magnetic Resonance (CT/MR) in total of the lesions as well as different aspects of metastasis in individuals with ovarian cancers (OC).
Materials And Methods: The PubMed, Embase, Cochrane library, and Web of Science databases were thoroughly searched until the cut-off date of July 23, 2024. The assessment of 68Ga-FAPI PET CT/MR of OC was presented by the included studies.
Novel Clinical PET Tracers in the Pipeline for Melanoma.
Curr Oncol Rep
March 2025
Department of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Purpose: The aim of this review is to provide an overview of novel clinical PET tracers in the pipeline for melanoma. Secondarily, to provide a head-to-head comparison with the current clinical standard used in clinical practice, [F]FDG, if available.
Recent Findings: [F]FDG PET/CT has become important in the clinical setting for melanoma as it serves many purposes, but lacks other important qualities due its nonspecific nature.
Highlights from the breakout session: diagnosis and classification of vasculitis.
Rheumatology (Oxford)
March 2025
Rheumatology Department, Health New Zealand, Auckland, New Zealand.
The session on 'Diagnosis and Classification of Vasculitis' featured six oral presentations covering various aspects of vasculitis diagnosis and classification. The application of the Ankara criteria for IgA vasculitis in adults was evaluated, finding that while the criteria showed good sensitivity, their specificity was insufficient, suggesting the need for refinement. A clustering approach to classifying ANCA-associated vasculitis (AAV) identified five distinct clusters, which improved prediction of disease outcomes.
View Article and Find Full Text PDFMRI and F-FDG-PET/CT findings of cervical reactive lymphadenitis: a comparison with nodal lymphoma.
Pol J Radiol
January 2025
Department of Radiology, Gifu University, Gifu, Japan.
Purpose: This study aimed to compare the findings of magnetic resonance imaging (MRI) and F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) to differentiate reactive lymphadenitis from nodal lymphoma of the head and neck.
Material And Methods: This study included 138 patients with histopathologically confirmed cervical lymphadenopathy, including 35 patients with reactive lymphadenitis and 103 patients with nodal lymphoma, who had neck MRI ( = 63) and/or F-FDG-PET/CT ( = 123) before biopsy. The quantitative and qualitative MRI results and maximum standardised uptake value (SUV) were retrospectively analysed and compared between the 2 pathologies.
The value of whole-body MRI instead of only brain MRI in addition to 18 F-FDG PET/CT in the staging of advanced non-small-cell lung cancer.
Cancer Imaging
March 2025
Radiology, Department of Surgical Sciences, Uppsala University, Uppsala University Hospital, entry 70, 1st floor, Uppsala, 751 85, Sweden.
Background: Non-small cell lung cancer (NSCLC) is a common neoplasm with poor prognosis in advanced stages. The clinical work-up in patients with locally advanced NSCLC mostly includes F-fluorodeoxyglucose positron emission tomography computed tomography (F-FDG PET/CT) because of its high sensitivity for malignant lesion detection; however, specificity is lower. Diverging results exist whether whole-body MRI (WB-MRI) improves the staging accuracy in advanced lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!